
Product Data Sheet

Product Name: ALK4290
Cat. No.: GC62833

Chemical Properties

Cas. No. 1251528-23-0

Formula $C_{27}H_{34}ClN_5O_3$

M.Wt 512.04

Solubility DMSO : 50 mg/mL (97.65 mM; ultrasonic and warming and heat to 60°C)

Storage

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure

Background

ALK4290 (AKST4290) is a potent and orally actively CCR3 inhibitor extracted from patent US20130261153A1, compound Example 2, with a K_i of 3.2 nM for hCCR3[1]. ALK4290 can be used for the research of neovascular age-related macular degeneration and Parkinsonism[2][3].

[1]. NIVENS MC, et, al. Use of ccr3-inhibitors. US20130261153A1.

[2]. Samanta A, te, al. Emerging Therapies in Neovascular Age-Related Macular Degeneration in 2020. Asia Pac J Ophthalmol (Phila). May-Jun 2020; 9(3):250-259.

[3]. Clinical Development of AKST4290 as a Novel Parkinson's Therapeutic

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA